Goldfinch Bio Honored by Goldman Sachs for Entrepreneurship

-- Anthony Johnson, M.D., President and CEO of Goldfinch Bio, Among 100 Most Intriguing Entrepreneurs at 2020 Builders + Innovators Summit --

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Goldfinch Bio, a clinical stage biotechnology company focused on discovering and developing precision medicines for the treatment of kidney diseases, today announced that Goldman Sachs (NYSE:GS) is recognizing Anthony Johnson, M.D., Goldfinch Bio’s President and Chief Executive Officer, as one of the 100 Most Intriguing Entrepreneurs of 2020 at its Builders + Innovators Summit.

Goldman Sachs selected Dr. Johnson as one of 100 entrepreneurs from multiple industries to be honored at the two-day event. Dr. Johnson has over 25 years of academic, industry and venture experience and, prior to joining Goldfinch Bio, spent several years in senior leadership roles driving research and development. Altogether, he has advanced more than 25 positive proof-of-concept studies to completion, contributing to multiple drug filings and approvals.

“I am honored to be recognized by Goldman Sachs among this group of entrepreneurs, all of whom are building diverse businesses with the common goal of delivering meaningful benefit to our global community,” said Anthony Johnson, M.D., President and Chief Executive Officer of Goldfinch Bio. “The spirit of this award aligns with our core mission at Goldfinch Bio, where we are focused on transforming the treatment paradigm for millions of people living with kidney diseases by delivering precision medicines that protect against the inevitability of dialysis and transplant. I am proud of the tremendous progress our team has made since our founding, and I look forward to continuing to partner with my colleagues to build Goldfinch Bio into the world’s leading kidney therapeutics company.”

“True innovation is built from a diversity of perspectives and experiences,” said David M. Solomon, Chief Executive Officer of Goldman Sachs. “Our Builders + Innovators Summit brings together a collective of impressive future leaders who are striving to drive meaningful change. For over 150 years, Goldman Sachs has supported entrepreneurs as they launch and grow their businesses. That’s why we are pleased to recognize Tony as one of the most intriguing entrepreneurs of 2020.”

In addition to honoring 100 entrepreneurs, the summit, which this year will take place virtually, consists of general sessions and clinics led by seasoned entrepreneurs, academics and business leaders as well as resident scholars.

About Goldfinch Bio

Goldfinch Bio, Inc. is a clinical stage biotechnology company that leverages a genomics-based, precision medicine approach to discovering and developing kidney disease treatments. Its Kidney Genome Atlas (KGA™) is a proprietary biology platform that drives candidate discovery, biomarker development and patient selection. The Company’s lead candidate, GFB-887, is a TRPC5 ion channel inhibitor, in Phase 2 development for the treatment of kidney diseases. Goldfinch Bio is also developing GFB-024, a peripherally-restricted cannabinoid receptor 1 (CB1) inverse agonist monoclonal antibody, for the treatment of rare and metabolic kidney diseases and expects to submit an investigational new drug (IND) application in 2021. Goldfinch Bio, headquartered in Cambridge, Massachusetts, was launched in 2016 by Third Rock Ventures and named in 2020 as one of FierceBiotech’s “Fierce 15.” Goldfinch Bio has an established strategic collaboration with Gilead Sciences, Inc. For more information, visit www.goldfinchbio.com.